Price
No data yet.
Social Signal Score
Analyst Ratings
41 analystsRevenue
$1.02B+241.45%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Alexander Hardy
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 3,221
- Beta
- 0.21
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- 1.95
Financials
Revenue
$1.02B+241.4%Net Income
$-122.83MEBITDA
$54.32MFree Cash Flow
$159.92MEPS (diluted)
$-0.63Shares Outstanding (diluted)
193.59M+12.4%Operating Expenses
$514.17MCash & Debt
$736.01MReturn of Capital
$3.83MRevenue by Segment (annual)
$3.22BQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $3.22B | $348.90M | $1.82 |
| 2024 | $2.85B | $426.86M | $2.25 |
| 2023 | $2.42B | $167.65M | $0.89 |
| 2022 | $2.10B | $141.56M | $0.76 |
| 2021 | $1.85B | $-64.08M | $-0.35 |
| 2020 | $1.86B | $854.03M | $4.75 |
| 2019 | $1.70B | $-23.85M | $-0.13 |
| 2018 | $1.49B | $-77.21M | $-0.44 |
| 2017 | $1.31B | $-117.04M | $-0.67 |
| 2016 | $1.12B | $-630.21M | $-3.80 |
| 2015 | $889.89M | $-171.80M | $-1.07 |
| 2014 | $749.28M | $-133.97M | $-0.92 |
| 2013 | $548.49M | $-176.35M | $-1.28 |
| 2012 | $500.72M | $-114.35M | $-0.95 |
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $2.67
- Implied price
- $88.21
- Return from $60.41
- 7.9% a year
To earn 15.0% a year on these assumptions you'd need to buy at $43.86 — -27.4% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 23 | 28 | 33 | 38 | 43 |
|---|---|---|---|---|---|
| -2.0% | -8.9% | -5.3% | -2.1% | 0.7% | 3.2% |
| 3.0% | -4.3% | -0.5% | 2.9% | 5.8% | 8.5% |
| 8.0% | 0.4% | 4.4% | 7.9% | 11.0% | 13.7% |
| 13.0% | 5.0% | 9.2% | 12.9% | 16.1% | 19.0% |
| 18.0% | 9.6% | 14.0% | 17.9% | 21.2% | 24.3% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
83-28.28%Social Signal Score
Mentions (49)
- News (RSS)seekingalpha·23h ago·Neutral
BioMarin Pharmaceutical Inc. (BMRN) Presents at Jefferies London Healthcare Conference - Slideshow
View source ↗ - News (Marketaux)seekingalpha.com·23h ago·Neutral
BioMarin Pharmaceutical Inc. (BMRN) Presents at Jefferies London Healthcare Conference - Slideshow BioMarin Pharmaceutical Inc. (BMRN) Presents at Jefferies London Healthcare Conference - Slideshow
View source ↗ - Newsmarketbeat.com·3d ago·Neutral
BioMarin Pharmaceutical Bets on Amicus Growth as VOXZOGO Competition Concerns Mount BioMarin Pharmaceutical NASDAQ: BMRN is betting that a growing rare-disease pipeline and its integration of Amicus will help sustain growth, as executives seek to address investor concerns about competition for its VOXZOGO treatment.
View source ↗ - Newsseekingalpha.com·5d ago·Positive
BioMarin Pharmaceutical Inc. (BMRN) Presents at Jefferies Global Healthcare Conference 2026 Transcript BioMarin Pharmaceutical Inc. (BMRN) Presents at Jefferies Global Healthcare Conference 2026 Transcript
View source ↗ - Newsmarketbeat.com·6d ago·Negative
BioMarin Pharmaceutical Sees $2.6 Billion Sales Potential in Amicus Drugs as VOXZOGO Expansion Looms BioMarin Pharmaceutical NASDAQ: BMRN expects growth from its acquired rare disease treatments, an expanded market for VOXZOGO and a pipeline that could deliver patient data in 2027, Chief Executive Officer Alexander Hardy said at the UBS Global Biopharma Conference.
View source ↗ - Newsseekingalpha.com·18d ago·Negative
…ed with my previous Hold rating on this name. Voxzogo's potential hypochondroplasia expansion is a nice growth catalyst, and a full approval would further strengthen BMRN's existing achondroplasia franchise. Their Amicus acquisition also brings new revenue sources, though I reckon it remains to be seen if it fully justifies the debt required to finance the transaction.
View source ↗ - Newsprnewswire.com·18d ago·Neutral
BioMarin to Participate in Upcoming Investor Conferences Stifel Healthcare Conference, November 11 at 3:20 pm EST UBS Global Biopharma Conference, November 16 at 9:20 am GMT Jefferies Global Healthcare Conference, November 17 at 11:30 am GMT SAN RAFAEL, Calif., Nov. 4, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will present at upcoming investor conferences in November.
View source ↗ - News (RSS)seekingalpha·19d ago·Positive
BioMarin Pharmaceutical Inc. (BMRN) Q3 2026 Earnings Call Transcript
View source ↗ - News (RSS)fool·19d ago·Positive
BioMarin (BMRN) Q3 2026 Earnings Call Transcript Revenue topped $1 billion for first time, fueled by Amicus integration.
View source ↗ - Newsseekingalpha.com·19d ago·Positive
BioMarin Pharmaceutical Inc. (BMRN) Q3 2026 Earnings Call Transcript BioMarin Pharmaceutical Inc. ( BMRN ) Q3 2026 Earnings Call November 2, 2026 4:30 PM EST Company Participants Traci McCarty - Group Vice President Alexander Hardy - President, CEO & Director Cristin Hubbard - Executive VP & Chief Commercial Officer Gregory Friberg - Executive VP and Chief Research & Development Officer Brian Mueller - CFO & Executive VP of Finance Conference Call Participants Sean Laaman - Morgan Stanley, Resea…
View source ↗ - Newsmarketbeat.com·20d ago·Negative
BioMarin Pharmaceutical Q3 Earnings Call Highlights BioMarin Pharmaceutical NASDAQ: BMRN reported third-quarter revenue above $1 billion for the first time, driven by growth across its rare-disease portfolio and contributions from acquired Amicus Therapeutics products. The company said revenue increased 32% year over year, while its metabolic conditions business grew 44%.
View source ↗ - Newszacks.com·20d ago·Neutral
BioMarin (BMRN) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates The headline numbers for BioMarin (BMRN) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
View source ↗ - Newszacks.com·20d ago·Neutral
BioMarin Pharmaceutical (BMRN) Q3 Earnings Surpass Estimates BioMarin Pharmaceutical (BMRN) came out with quarterly earnings of $0.23 per share, beating the Zacks Consensus Estimate of a loss of $0.09 per share. This compares to earnings of $0.12 per share a year ago.
View source ↗ - Newsprnewswire.com·20d ago·Negative
BioMarin Reports Third Quarter 2026 Financial and Operating Results Third Quarter 2026 Total Revenues Increased 32% Y/Y to $1.025 billion; Growth Driven by 44% Increase in Metabolic Conditions Y/Y, and 12% Increase in Skeletal Conditions Y/Y Updates Full-year 2026 Guidance to Reflect Order Timing Uncertainty and Impact of Two Acquired In-process Research and Development (IPR&D) Charges Recently Announced the Addition of a New Investigational Fabry Asset to Clinical Portfolio PDUFA Action Date of
View source ↗ - Newsprnewswire.com·24d ago·Neutral
…d commercial milestones, and tiered royalties on net sales of HM15421/GC1134A SAN RAFAEL, Calif., Oct. 29, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced it has entered into an exclusive worldwide license agreement with GC Biopharma Corp. and Hanmi Pharm Co., Ltd.
View source ↗ - Newsprnewswire.com·27d ago·Neutral
BioMarin to Host Third Quarter 2026 Financial Results Conference Call and Webcast on Monday, November 2, 2026, at 4:30pm ET SAN RAFAEL, Calif., Oct. 26, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a conference call and webcast on Monday, November 2, 2026, at 4:30 p.m.
View source ↗ - Newszacks.com·34d ago·Neutral
BioMarin Pharmaceutical (BMRN) Earnings Expected to Grow: Should You Buy? BioMarin (BMRN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
View source ↗ - Newsprnewswire.com·44d ago·Neutral
…niocervical junction growth in children with achondroplasia, including infants SAN RAFAEL, Calif., Oct. 9, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced it will present new data from 13 studies at the American Society for Bone and Mineral Research 2026 Annual Meeting (ASBMR) in Boston, including results from studies of VOXZOGO® (vosoritide) in children with achondroplasia and hypochondroplasia.
View source ↗ - News (RSS)seekingalpha·47d ago·Neutral
BioMarin Q3 financial results to see IPR&D expense impact of $283M
View source ↗ - Newsprnewswire.com·48d ago·Neutral
BioMarin Appoints Cara Bauer as Chief People Officer Ms. Bauer Brings More Than 25 Years of Experience in Human Resources, Across Biotechnology and Technology Industries Appointment Effective Oct. 5, 2026 SAN RAFAEL, Calif., Oct. 5, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that Cara Bauer, Ph.D.
View source ↗ - Newscnbc.com·51d ago·Neutral
BioMarin reports five-year Pompe disease data showing durable motor function A BioMarin combination therapy helped adults with late-onset Pompe disease maintain walking distance over five years of continuous therapy. Respiratory function remained relatively stable, with no new safety signals identified.
View source ↗ - Newsprnewswire.com·51d ago·Positive
…durable efficacy and safety of POMBILITI + OPFOLDA in late-onset Pompe disease SAN RAFAEL, Calif., Oct. 2, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced new data evaluating the efficacy and safety of POMBILITI® (cipaglucosidase alfa-atga) + OPFOLDA® (miglustat) in late-onset Pompe disease (LOPD) were presented at the 31st Annual Congress of the World Muscle Society (WMS), in Hiroshima, Japan.
View source ↗ - Newsseekingalpha.com·62d ago·Neutral
BioMarin: Why I See Significant Upside Into 2027 Q4 2026/ 2027 will be rich in catalysts for BioMarin Pharmaceutical Inc. From the presentation of 12 mg/kg BMN 351 Phase 1/2 data in Duchenne muscular dystrophy by year-end 2026 to a potential H1 2027 approval of Voxzogo for hypochondroplasia. BioMarin raised its full-year 2026 revenue guidance from $3.83 billion-$3.93 billion to $3.88 billion-$3.93 billion.
View source ↗ - Newsmarketbeat.com·65d ago·Negative
BioMarin Targets Amicus Synergies as VOXZOGO Nears $1B Milestone BioMarin Pharmaceutical NASDAQ: BMRN said it is progressing with the integration of Amicus Therapeutics while pursuing additional business-development opportunities, as executives outlined growth plans for newly acquired rare-disease products, VOXZOGO and several pipeline programs at Morgan Stanley's Global Healthcare Conference.
View source ↗ - Newszacks.com·67d ago·Negative
BioMarin Stops Voxzogo Development for Noonan Syndrome BMRN ends Voxzogo development for Noonan syndrome as the drug faces new competition and pursues other growth opportunities.
View source ↗ - Newsseekingalpha.com·69d ago·Positive
BioMarin Pharmaceutical Inc. (BMRN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript BioMarin Pharmaceutical Inc. (BMRN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newsprnewswire.com·69d ago·Neutral
BioMarin Announces Appointment of Robert Plenge, M.D., Ph.D., Chief Research Officer of Bristol Myers Squibb, to Board of Directors SAN RAFAEL, Calif., Sept. 14, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced that the company has appointed Robert Plenge, M.D.
View source ↗ - News (RSS)yahoo·71d ago·Neutral
BioMarin Shares Jump 5% After Global Patent Settlement With Ascendis
View source ↗ - News (Marketaux)insidermonkey.com·71d ago·Positive
BioMarin Shares Jump 5% After Global Patent Settlement With Ascendis BioMarin Pharmaceutical</em[+262 characters]
View source ↗ - News (Marketaux)gurufocus.com·72d ago·Neutral
BioMarin Pharmaceutical Inc. at Citi Biopharma Back to School Summit Transcript Refinitiv StreetEvents Event Transcript [+95 characters]
View source ↗ - Newsseekingalpha.com·73d ago·Positive
BioMarin Pharmaceutical Inc. (BMRN) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript BioMarin Pharmaceutical Inc. (BMRN) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
View source ↗ - Newsseekingalpha.com·73d ago·Positive
BioMarin Pharmaceutical Inc. (BMRN) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript BioMarin Pharmaceutical Inc. (BMRN) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
View source ↗ - News (RSS)seekingalpha·73d ago·Positive
BioMarin Pharmaceutical Inc. (BMRN) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
View source ↗ - Newsseekingalpha.com·74d ago·Positive
BioMarin Pharmaceutical Inc. (BMRN) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript BioMarin Pharmaceutical Inc. (BMRN) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
View source ↗ - Newsprnewswire.com·74d ago·Negative
…t expanding treatment with VOXZOGO to include children with hypochondroplasia SAN RAFAEL, Calif., Sept. 9, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced new data from the Phase 3 CANOPY-HCH-3 study evaluating VOXZOGO® (vosoritide) in children with hypochondroplasia were published in New England Journal of Medicine (NEJM) Evidence and presented at the European Society for Paediatric Endocrinology (ESPE) 2026 Annual Meeting.
View source ↗ - News (RSS)yahoo·79d ago·Negative
BioMarin (BMRN) Secured 20% U.S. Royalties on Yuviwel. Is Monetizing a Rival Better than Blocking It?
View source ↗ - Newszacks.com·80d ago·Negative
How BioMarin Turned a Competitive Threat Into a Royalty-Bearing Asset BMRN turns a competitive threat into a royalty stream as Ascendis pays royalties on Yuviwel sales, reshaping the economics of competition.
View source ↗ - Newsprnewswire.com·82d ago·Neutral
BioMarin Announces Close of the Alesta Therapeutics Acquisition Acquisition adds ALE1, a potential first oral therapy for hypophosphatasia to clinical pipeline SAN RAFAEL, Calif., Sept. 1, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) said today that it completed the previously announced agreement to acquire Alesta Therapeutics.
View source ↗ - News (RSS)zerohedge·83d ago·Neutral
…xception of NVDA which rises 0.6% after Friday's slide (Apple -0.3%, Meta -0.1%, Amazon -0.4%, Alphabet -0.5%, Tesla -0.6%, Microsoft -0.6%) BioMarin Pharmaceutical (BMRN) rises 4% after the company said it had entered into binding terms with Ascendis Pharma, resolving the patent and ancillary disputes concerning Ascendis’s Yuviwel. Energy stocks (CVX +2%, XOM +2%) rise with oil as tensions spiked in the Middle East, with the US and Iran exchanging strikes for the first time in about a month and…
View source ↗ - News (RSS)investing·83d ago·Neutral
BioMarin stock jumps after Ascendis patent settlement deal
View source ↗ - Newsgurufocus.com·83d ago·Neutral
BioMarin Announces Global Settlement with Ascendis Pharma A/S; Ascendis Will Pay Royalties to BioMarin on Yuviwel Sales in U.S., EU, Brazil and South Korea BioMarin Announces Global Settlement with Ascendis Pharma A/S; Ascendis Will Pay Royalties to BioMarin on Yuviwel Sales in U.S., EU, Brazil and
View source ↗ - News (RSS)yahoo·95d ago·Neutral
BioMarin Pharmaceutical (BMRN)’s Alesta Deal Adds New Growth Potential in Rare Diseases
View source ↗ - Newscnbc.com·95d ago·Negative
BioMarin to acquire Alesta Therapeutics for $275 million for potential rare bone disease treatment BioMarin will acquire Alesta Therapeutics for $275 million upfront, and up to an additional $215 million based on milestones. Alesta Therapeutic's lead drug is a potential treatment for hypophosphatasia (HPP).
View source ↗ - News (RSS)investing·96d ago·Neutral
Why is BioMarin Pharmaceutical stock surging today?
View source ↗ - Newszacks.com·101d ago·Positive
5 Undervalued Price-to-Book Stocks Worth Buying in August BioMarin, Invesco, Centene, HPE and Gibraltar Industries stand out as undervalued stocks with low price-to-book ratios.
View source ↗ - Newszacks.com·102d ago·Positive
BMRN vs. ILMN: Which Stock Is the Better Value Option? Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either BioMarin Pharmaceutical (BMRN) or Illumina (ILMN). But which of these two companies is the best option for those looking for undervalued stocks?
View source ↗ - Newsseekingalpha.com·102d ago·Positive
BioMarin Pharmaceutical Inc. (BMRN) Presents at Canaccord Genuity's 46th Annual Growth Conference Transcript BioMarin Pharmaceutical Inc. (BMRN) Presents at Canaccord Genuity's 46th Annual Growth Conference Transcript
View source ↗ - Newsmarketbeat.com·102d ago·Neutral
BioMarin Targets Faster Deleveraging as Amicus Deal Expands Rare-Disease Growth BioMarin Pharmaceutical NASDAQ: BMRN outlined its growth strategy, integration plans for Amicus Therapeutics and pipeline priorities during a Canaccord discussion with Chief Financial Officer Brian Mueller.
View source ↗ - Newsprnewswire.com·104d ago·Neutral
BioMarin to Participate at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026, at 8:00AM ET in Boston SAN RAFAEL, Calif., Aug. 10, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced management will present at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026, at 8:00AM ET in Boston.
View source ↗
Earnings
Mon, Feb 22(in 3 months)
Consensus estimate $0.82 per share
Typical surprise +26.7% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Nov 2$0.23 vs $-0.05beat
- Thu, Aug 6$1.20 vs $0.95beat
- Mon, May 4$0.76 vs $0.78miss
- Mon, Feb 23$-0.24 vs $0.17miss
- Mon, Oct 27$-0.16 vs $-0.15miss
- Mon, Aug 4$1.23 vs $0.86beat
Estimates and results for BMRN via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by BMRN officers and directors.
- Bought
- —
- Sold
- $4.8m
0 trades
9 trades
- Friberg Gregory Rsold
- Davis George Ericsold
- Friberg Gregory Rsold
- Guyer Charles Gregsold
- Friberg Gregory Rsold
- Davis George Ericsold
- Burkhart Erinsold
- Hubbard Cristinsold
91 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Daniel Goldmanhouse · NY10 · disclosed Apr 17, 2023 (42d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Apr 7, 2023 (24d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Jan 3, 2023 (28d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Jun 10, 2022 (31d later)Sell$1,001 - $15,000
- Josh Gottheimerhouse · NJ05 · disclosed Nov 15, 2021 (28d later)Sell$1,001 - $15,000
- Gilbert Cisneroshouse · CA31 · disclosed Jan 11, 2021 (12d later)Buy$15,001 - $50,000
- Josh Gottheimerhouse · NJ05 · disclosed Nov 5, 2020 (20d later)Buy$1,001 - $15,000
- Josh Gottheimerhouse · NJ05 · disclosed Oct 13, 2020 (28d later)Sell$1,001 - $15,000
- Josh Gottheimerhouse · NJ05 · disclosed Jan 6, 2020 (26d later)Buy$1,001 - $15,000
- Josh Gottheimerhouse · NJ05 · disclosed Jan 6, 2020 (21d later)Buy$1,001 - $15,000
- Alan Lowenthalhouse · CA47 · disclosed Sep 1, 2019 (17d later)Sell$1,001 - $15,000
- Alan Lowenthalhouse · CA47 · disclosed Sep 1, 2019 (18d later)Sell$1,001 - $15,000
- Alan Lowenthalhouse · CA47 · disclosed Sep 1, 2019 (18d later)Sell$15,001 - $50,000
- Alan Lowenthalhouse · CA47 · disclosed Sep 1, 2019 (17d later)Sell$50,001 - $100,000
- Van Taylorhouse · TX03 · disclosed Apr 15, 2019 (21d later)Sell$1,001 - $15,000
- Alan Lowenthalhouse · CA47 · disclosed Jun 10, 2018 (12d later)Buy$50,001 - $100,000
- Alan Lowenthalhouse · CA47 · disclosed May 3, 2018 (6d later)Buy$1,001 - $15,000
- Alan Lowenthalhouse · CA47 · disclosed May 3, 2018 (7d later)Buy$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
